Ballicules.com

Flurazepam

DALMANE

What it isLong-acting benzodiazepine GABA-A modulator approved for insomnia.

Why this oneLong-lived active metabolites sustain sleep, but this rarely outweighs the next-day burden.

What limits itAccumulation causes prolonged sedation, impaired driving, falls, and confusion, particularly in older adults; dependence limits chronic use.

FDA-approved for

FDA label

BOXED WARNING Concomitant opioid use risks profound sedation, respiratory depression, coma, death; risk of abuse, misuse, addiction; dependence and withdrawal reactions.
FDA dosingPopulationStartTargetMax
InsomniaWomen15 mg QHS15 mg QHS30 mg QHS
InsomniaMen15-30 mg QHS15-30 mg QHS30 mg QHS
InsomniaElderly or debilitated15 mg QHS15 mg QHS15 mg QHS

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Neonates exposed late in pregnancy may experience sedation and/or neonatal withdrawal; observational data do not report clear association with major birth defects.

Lactation Breastfeeding not recommended.

⚠ BOXED WARNINGS

Cost, est. cash$10–$500/month

Generic entry1985

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability3 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryX

Defining liabilitySedation, falls, dependence and additive respiratory depression with opioids or other CNS depressants.

Mechanism of action: Flurazepam ballicule

Flurazepam ballicule: receptor binding, kinetics and half-life diagram

Open Flurazepam in the interactive console ↗

Memory aids: mascots and interaction avatars

Flurazepam DALMANE mascot mnemonic cartoon
“Dalmatian on Floor”
long dog → long half-life
hot pink → benzo theme
Flurazepam CYP3A4 substrate avatar
CYP3A4 substrate

Open Flurazepam in the interactive console ↗